Atrial natriuretic peptide augments the variability of sympathetic nerve activity in human heart failure

Activation of the sympathetic nervous system, decreased heart rate variability (HRV), and loss of modulation of muscle sympathetic nerve activity (MSNA) within the low frequency (LF, 0.05-0.15 Hz) range are three adverse features of advanced congestive heart failure (CHF). In healthy men, atrial nat...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hypertension Vol. 19; no. 3 Pt 2; p. 619
Main Authors: Kubo, T, Ando, S, Picton, P, Atchison, D J, Notarius, C F, Pollard, M J, Abramson, B L, Floras, J S
Format: Journal Article
Language:English
Published: England 01.03.2001
Subjects:
Adult
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Atrial Natriuretic Factor - pharmacology
Cardiac Output, Low - physiopathology
Cardiomyopathy, Dilated - drug therapy
Cardiomyopathy, Dilated - physiopathology
Heart Rate - drug effects
Humans
Male
Middle Aged
Nitroglycerin - therapeutic use
Sympathetic Nervous System - drug effects
Sympathetic Nervous System - physiopathology
Vasodilator Agents - therapeutic use
ISSN:0263-6352
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Activation of the sympathetic nervous system, decreased heart rate variability (HRV), and loss of modulation of muscle sympathetic nerve activity (MSNA) within the low frequency (LF, 0.05-0.15 Hz) range are three adverse features of advanced congestive heart failure (CHF). In healthy men, atrial natriuretic peptide (ANP) infusion attenuates reflex increases in MSNA and reduces LF components of HRV spectral power. Sympathoinhibitory actions have also been documented in CHF, but effects on the variability of MSNA and HRV have not been described. Heart rate and MSNA were recorded in 10 men (aged 39 +/- 3 years, mean +/- SE) with dilated cardiomyopathy (mean EF 20 +/- 4%) treated with angiotensin converting enzyme (ACE) inhibitors. Subjects received i.v. ANP (50 microg bolus then 50 ng/kg/min) and nitroglycerin (NTG, 8 mg/min) as a hemodynamic control. Signals at baseline, and 13-20 min into each infusion were submitted to spectral analysis. ANP had no effect on HRV, but increased MSNA LF (from 7.9 +/- 1.5 to 12.1 +/- 2.6 U2; P< 0.02) and total spectral power (from 47.9 +/- 5.4 to 61.9 +/- 6.8 U2; P < 0.05). NTG had no effect on the variability of MSNA or HRV. In CHF patients receiving ACE inhibitors, ANP (i) does not suppress HRV and (ii) enhances the modulation of MSNA, particularly within the LF range. This latter action is not observed with NTG. These findings suggest beneficial actions of exogenous ANP on neurogenic circulatory control.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0263-6352
DOI:10.1097/00004872-200103001-00015